Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.
- DOI
- 10.1136/bmjph-2024-002441
- Published
- 2025
- Container
- BMJ public health
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjph-2024-002441,
title = {Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.},
author = {Gil-Prieto R and Pérez-Martín J and Díaz Aguiló A and Soudani S and Platero-Alonso L and López-Belmonte JL and de la Cuadra-Grande A and Casado MÁ and Álvarez Aldean J},
year = {2025},
journal = {BMJ public health},
doi = {10.1136/bmjph-2024-002441},
url = {https://doi.org/10.1136/bmjph-2024-002441}
}RIS
TY - JOUR TI - Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study. AU - Gil-Prieto R AU - Pérez-Martín J AU - Díaz Aguiló A AU - Soudani S AU - Platero-Alonso L AU - López-Belmonte JL AU - de la Cuadra-Grande A AU - Casado MÁ AU - Álvarez Aldean J PY - 2025 JO - BMJ public health DO - 10.1136/bmjph-2024-002441 UR - https://doi.org/10.1136/bmjph-2024-002441 ER -
APA
R, G., J, P., A, D. A., S, S., L, P., JL, L., A, D. L. C., MÁ, C., & J, Á. A. (2025). Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.. BMJ public health. https://doi.org/10.1136/bmjph-2024-002441
Source records
- pubmed · retrieved 2026-09-26T01:43:36.900Z